Related Experiment Video

Updated: Mar 7, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

VEGF inhibitors in renal cell carcinoma

Pankit Vachhani1, Saby George1

  • 1Roswell Park Cancer Institute, Buffalo, New York.

Clinical Advances in Hematology & Oncology : H&O
|February 18, 2017
PubMed

Insights

Targeted therapies, including vascular endothelial growth factor (VEGF) inhibitors, have significantly improved survival for advanced renal cell carcinoma (RCC). These treatments offer new hope for patients, nearly tripling overall survival rates.

Area of Science:

  • Oncology
  • Pharmacology
  • Genitourinary Cancers

Background:

  • Renal cell carcinoma (RCC) management has been revolutionized by targeted therapies.
  • Vascular Endothelial Growth Factor (VEGF) pathway inhibitors and Programmed Death 1 (PD-1) inhibitors have transformed outcomes.
  • Advanced RCC, previously with a median survival of ~1 year, now shows significantly improved prognoses.

Purpose of the Study:

  • To review the impact of targeted therapies on advanced renal cell carcinoma.
  • To discuss pivotal clinical trials involving VEGF inhibitors in various settings.
  • To explore future directions and practical considerations for VEGF inhibitor use in RCC.

Main Methods:

  • Review of seminal research on the von Hippel-Lindau/hypoxia-inducible factor axis in RCC.
  • Analysis of key clinical trials investigating VEGF inhibitors in metastatic, adjuvant, and neoadjuvant RCC.
  • Discussion of current clinical practices and future research avenues for VEGF inhibitors.

Main Results:

  • Targeted therapies, including VEGF and PD-1 inhibitors, have nearly tripled overall survival in advanced RCC.
  • These agents have shifted the paradigm from a fatal diagnosis to offering potential cures.
  • VEGF inhibitors show efficacy in metastatic, adjuvant, and neoadjuvant settings.

Conclusions:

  • VEGF pathway inhibitors represent a major advancement in renal cell carcinoma treatment.
  • Continued research and practical considerations are essential for optimizing VEGF inhibitor therapy.
  • The advent of targeted therapies offers unprecedented hope for advanced RCC patients.

More Related Videos

Intravascular Delivery of Biologics to the Rat Kidney07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

8.2K
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

10.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K